MetLife Investment Advisors LLC trimmed its holdings in shares of Zoetis Inc (NYSE:ZTS) by 2.9% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 142,439 shares of the company’s stock after selling 4,205 shares during the period. MetLife Investment Advisors LLC’s holdings in Zoetis were worth $12,134,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the company. Valeo Financial Advisors LLC increased its stake in shares of Zoetis by 34.4% during the 2nd quarter. Valeo Financial Advisors LLC now owns 2,210 shares of the company’s stock worth $202,000 after purchasing an additional 566 shares in the last quarter. Dupont Capital Management Corp increased its stake in shares of Zoetis by 2.5% during the 2nd quarter. Dupont Capital Management Corp now owns 24,508 shares of the company’s stock worth $2,088,000 after purchasing an additional 601 shares in the last quarter. Dorsey Wright & Associates increased its stake in shares of Zoetis by 7.9% during the 2nd quarter. Dorsey Wright & Associates now owns 8,386 shares of the company’s stock worth $714,000 after purchasing an additional 617 shares in the last quarter. Wrapmanager Inc. grew its stake in Zoetis by 7.9% in the 2nd quarter. Wrapmanager Inc. now owns 9,176 shares of the company’s stock worth $782,000 after acquiring an additional 672 shares during the period. Finally, Sequoia Financial Advisors LLC grew its stake in Zoetis by 23.0% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 3,746 shares of the company’s stock worth $319,000 after acquiring an additional 700 shares during the period. 89.79% of the stock is owned by institutional investors and hedge funds.

In other news, insider Catherine A. Knupp sold 46,816 shares of the business’s stock in a transaction on Wednesday, August 15th. The shares were sold at an average price of $90.84, for a total transaction of $4,252,765.44. Following the completion of the sale, the insider now directly owns 81,640 shares of the company’s stock, valued at approximately $7,416,177.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Roxanne Lagano sold 2,000 shares of the business’s stock in a transaction on Monday, July 2nd. The shares were sold at an average price of $84.76, for a total transaction of $169,520.00. Following the sale, the insider now directly owns 22,023 shares of the company’s stock, valued at $1,866,669.48. The disclosure for this sale can be found here. Insiders have sold a total of 213,467 shares of company stock valued at $19,488,185 over the last three months. Corporate insiders own 0.35% of the company’s stock.

Several analysts have commented on the stock. Stifel Nicolaus cut shares of Zoetis from a “buy” rating to a “hold” rating and set a $95.00 target price for the company. in a research note on Tuesday, August 21st. They noted that the move was a valuation call. Morgan Stanley lifted their target price on shares of Zoetis from $87.00 to $92.00 and gave the stock a “hold” rating in a research note on Friday, August 3rd. Argus lifted their target price on shares of Zoetis from $90.00 to $103.00 and gave the stock a “buy” rating in a research note on Tuesday, August 14th. Zacks Investment Research raised shares of Zoetis from a “hold” rating to a “buy” rating and set a $101.00 target price for the company in a research note on Monday. Finally, BMO Capital Markets reaffirmed a “hold” rating and issued a $82.00 target price on shares of Zoetis in a research note on Thursday, August 2nd. Seven analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $91.73.

Shares of NYSE ZTS opened at $89.70 on Friday. Zoetis Inc has a 52-week low of $62.79 and a 52-week high of $93.67. The firm has a market cap of $42.78 billion, a PE ratio of 37.38, a P/E/G ratio of 1.82 and a beta of 1.02. The company has a debt-to-equity ratio of 2.50, a current ratio of 4.38 and a quick ratio of 2.92.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, August 2nd. The company reported $0.77 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.71 by $0.06. Zoetis had a net margin of 19.95% and a return on equity of 72.30%. The company had revenue of $1.42 billion during the quarter, compared to analysts’ expectations of $1.38 billion. During the same period in the previous year, the company earned $0.53 EPS. The business’s quarterly revenue was up 11.5% compared to the same quarter last year. sell-side analysts expect that Zoetis Inc will post 3.07 EPS for the current fiscal year.

Zoetis Company Profile

Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Further Reading: What is a closed-end mutual fund (CEF)?

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.